Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties.
Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. · 2008
Read Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. by Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2518121.txt.
Introduction
Levina and colleagues asked in 2008 whether chemotherapy itself can leave behind lung cancer stem cells. These rare cells are blamed for tumours regrowing after treatment, because they resist drugs and can rebuild the tumour. The team treated human lung cancer cells with three standard drugs and studied the survivors.
The surviving cells carried stem cell markers such as CD133 and Oct-4 and could grow as spheres, renew themselves, and mature into ordinary cancer cells that regained drug sensitivity. In mice they formed tumours readily and spread widely. Their tumours held two to three times more growth and blood-vessel factors, such as VEGF and IL-6, than ordinary tumours did. The authors suggest blocking this factor network could improve therapy.
Catalog record
| CREATOR | Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties By Vera Levina, Adele M. Marrangoni, Richard DeMarco, Elieser Gorelik, Anna E. Lokshin, Nils Cordes Published in: PLoS ONE DOI: 10.1371/journal.pone.0003077 ABSTRACT Background Cancer stem cells (CSCs) are thought to be responsible for tumor regeneration after chemotherapy, although direct confirmation of this remains forthcoming. We therefore investigated whether drug treatment could enrich and maintain CSCs and whether the high tumorogenic and metastatic abilities of CSCs were based on their marked ability to produce growth and angiogenic factors and express their cognate receptors to stimulate tumor cell proliferation and stroma formation. Methodology/Findings Treatment of lung tumor cells with doxorubicin, cisplatin, or etoposide resulted in the selection of drug surviving cells (DSCs). These cells expressed CD133, CD117, SSEA-3, TRA1-81, Oct-4, and nuclear β-catenin and lost expression of the differentiation markers cytokeratins 8/18 (CK 8/18). DSCs were able to grow as tumor spheres, maintain self-renewal capacity, and differentiate. Differentiated progenitors lost expression of CD133, gained CK 8/18 and acquired drug sensitivity. In the presence of drugs, differentiation of DSCs was abrogated allowing propagation of cells with CSC-like characteristics. Lung DSCs demonstrated high tumorogenic and metastatic potential following inoculation into SCID mice, which supported their classification as CSCs. Luminex analysis of human and murine cytokines in sonicated lysates of parental- and CSC-derived tumors revealed that CSC-derived tumors contained two- to three-fold higher levels of human angiogenic and growth factors (VEGF, bFGF, IL-6, IL-8, HGF, PDGF-BB, G-CSF, and SCGF-β). CSCs also showed elevated levels of expression of human VEGFR2, FGFR2, CXCR1, 2 and 4 receptors. Moreover, human CSCs growing in SCID mice stimulated murine stroma to produce elevated levels of angiogenic and growth factors. Conclusions/Significance These findings suggest that chemotherapy can lead to propagation of CSCs and prevention of their differentiation. The high tumorigenic and metastatic potentials of CSCs are associated with efficient cytokine network production that may represent a target for increased efficacy of cancer therapy. INTRODUCTION In recent years, substantial experimental evidence has been generated in support of the role of a small population of self-renewing cells that could sustain malignant growth [1], [2]. This population was termed cancer-initiating cells or cancer stem cells (CSCs) for their high capacity for self-renewal, multilineage differentiation, and superior levels of malignancy. CSCs have been identified and isolated in various malignancies including breast, brain, prostate, pancreatic, lung, and colon cancer [3]–[11]. CSCs were identified utilizing flow-cytometry-based cell sorting and NOD/SCID mice xenografting. CSCs express tissue-specific cell surface markers: e.g., breast CSCs express CD44+/CD24low [3], and brain, prostate, lung and pancreatic CSCs express CD133+ [2], [4], [7], [8], [10]. Flow-cytometry-based cell-sorting which enables the isolation of a “side population” (SP) with enriched cancer stem cell activity was described by Goodell et al [12]. SP cells are characterized by distinct low Hoechst 33342 dye staining, attributed to the expression of ABCG2, an ATF-binding cassette (ABC) transporter [13]. SP cells also demonstrate a greater tumorigenic capacity than non-SP cells [13]–[15]. Flow-cytometry-based methods of sorting CSCs, using specific tissue CSC markers as well as the formation of spherical clusters of self-replicating cells [16]–[18], permit the isolation of a cell population enriched in early progenitor/stem cells. Due to their high drug resistance and tumorigenicity, CSCs are thought to be responsible for tumor regeneration after chemotherapy [19], [20], although direct confirmation of this is still forthcoming. We therefore hypothesize that CSCs can be enriched and subsequently isolated from tumor cell populations following drug treatment. In the present study drug surviving cells (DSCs) were isolated from human cancer cell lines treated with cisplatin, doxorubicin, or etoposide. Isolated DSCs exhibited high clonogenic capacities, enrichment with SP cells, expression of CSC cell surface and embryonic stem cell markers, a capacity for self-renewal, the generation of differentiated progeny, and high tumorigenic potential following SCID mice transplantation. We concluded that these DSCs were CSCs. It has also been suggested that CSCs have high metastatic potential [21]. Recently, the relationship between pancreatic CSCs and tumor metastasis was demonstrated [8]. We demonstrated that drug isolated lung CSCs have high metastatic potential. It continues to be unclear what properties of CSCs confer increased tumorigenicity and metastatic potential. We hypothesized that the tumorigenic and metastatic abilities of CSCs were based on their marked ability to produce growth and angiogenic factors, which stimulate tumor cell proliferation as well as promote formation of the tumor vascular system in order to provide oxygen and nutrients for local tumor growth or distant growth after dissemination of tumor cells into different anatomical locations. Thus, the highly efficient production of growth and angiogenic factors is a fundamental property of tumor-initiating cells. VEGF is a potent angiogenic factor [22], while growth factors such as bFGF, EGF, and HGF can stimulate proliferation of not only tumor cells but also endothelial cells and thus manifest proangiogenic and antiapoptotic effects [23]. Some data indicate that chemokines, such as IL-8 (CXCL8), MCP-1 (CCL2), and RANTES (CCL5), not only stimulate migration, but also proliferation of tumor and stromal cells, including endothelial cells [24]. Recently it was shown that IL-8 exhibits strong angiogenic activity via transactivation of VEGF receptor 2 (VEGFR2) [25]. Thus, different types of tumor producing factors (cytokines, chemokines, angiogenic and growth factors) have overlapping functions in promoting tumor growth. Numerous experimental and clinical data indicate that neutralization of growth or angiogenic factors, or blocking their receptor signaling, could inhibit tumor growth, confirming the importance of these factors in tumor cell proliferation [26]. Thus, production of growth and angiogenic factors by CSCs appears crucial for their tumorigenic and metastatic potentials. However, this CSC cytokine and growth/angiogenic factor network had not been previously investigated. Therefore, in the present study, we performed a comprehensive analysis of various cytokines, chemokines, and growth factors produced by parental H460 tumor cells and isolated CSCs using multiplex xMAP technology (Luminex Corp., Austin, TX), which allows simultaneous analysis of numerous soluble factors. This analysis was performed in vitro on cultured cells and in vivo utilizing the human tumor xenografted model in SCID mice. Human tumors growing in SCID mice consist of human tumor cells and murine stroma. Sonicated extracts of the xenografted human tumors contained cytokines produced by human tumor cells as well as by murine stromal cells. Concentrations of each type of cytokines can be analyzed using multiplex kits developed specifically for the detection of human or murine cytokines. This could provide information about the cytokine network produced by CSCs and their ability to stimulate stroma formation. Our studies demonstrate that drug surviving lung tumor cells have the characteristics of CSCs, and produce elevated levels of multiple cytokines, chemokines, growth and angiogenic factors and their receptors. These findings bring new insight to our understanding of the mechanisms responsible for high tumorigenic and metastatic potential of lung CSCs and their ability to survive chemotherapy. MATERIALS AND METHODS Cell lines Human cultured cancer cell lines, OVCAR-3 (ovarian), MCF-7 (breast), and H460 (lung), were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were grown in culture media, as recommended by ATCC, supplemented with 20% FBS (Millipore Inc., Billerica, MA). Reagents Cisplatin, doxorubicin, etoposide, and Hoechst 33342 were from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO). Fluorochrome-conjugated antibodies against human CD24, CD34, CD44, CD24, CD117, CD90, VLA-4, and VLA-5